{
    "clinical_study": {
        "@rank": "149734", 
        "arm_group": [
            {
                "arm_group_label": "FIAsp followed by NovoRapid\u00ae", 
                "arm_group_type": "Experimental", 
                "description": "Each subject will be randomly allocated to a treatment sequence consisting of 2 dosing visits separated by a wash-out period of 3-12 days"
            }, 
            {
                "arm_group_label": "NovoRapid\u00ae followed by FIAsp", 
                "arm_group_type": "Experimental", 
                "description": "Each subject will be randomly allocated to a treatment sequence consisting of 2 dosing visits separated by a wash-out period of 3-12 days"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Europe. The aim of the trial is to compare the pharmacokinetic\n      (the exposure of the trial drug in the body) and pharmacodynamic (the effect of the\n      investigated drug on the body) properties of FIAsp (faster-acting insulin aspart) and\n      insulin aspart (NovoRapid\u00ae) given as a bolus on top of a basal continuous subcutaneous\n      insulin infusion (CSII)."
        }, 
        "brief_title": "A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp When Administered as a Bolus in a Continuous Subcutaneous Infusion Regimen in Subjects With Type 1 Diabetes", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "condition": [
            "Diabetes", 
            "Diabetes Mellitus, Type 1"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female aged 18-64 years (both inclusive) at the time of signing informed\n             consent\n\n          -  Type 1 diabetes mellitus (as diagnosed clinically) for at least 12 months\n\n          -  Body mass index (BMI) 18.5-28.0 kg/m^2 (both inclusive)\n\n          -  Treated with multiple daily insulin injections or continuous subcutaneous insulin\n             infusion (CSII) for at least 12 months\n\n        Exclusion Criteria:\n\n          -  Subject who has donated any blood or plasma in the past month or more than 500 mL\n             within 3 months prior to screening\n\n          -  Smoker (defined as a subject who is smoking at least one cigarette, cigar or pipe\n             daily)\n\n          -  Not able or willing to refrain from smoking and use of nicotine substitute products\n             during the inpatient period"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "64 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01992588", 
            "org_study_id": "NN1218-3890", 
            "secondary_id": [
                "2011-000913-37", 
                "U1111-1119-5358"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "FIAsp followed by NovoRapid\u00ae", 
                "description": "Subjects - in a euglycaemic clamp setting - will receive a priming (initial) dose followed by a continuous basal rate infusion and finally a bolus dose on top of the basal rate infusion.\nThe trial products will be administered subcutaneously (s.c. under the skin) by means of an insulin pump.", 
                "intervention_name": "insulin aspart (FIAsp)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "NovoRapid\u00ae followed by FIAsp", 
                "description": "Subjects - in a euglycaemic clamp setting - will receive a priming (initial) dose followed by a continuous basal rate infusion and finally a bolus dose on top of the basal rate infusion.\nThe trial products will be administered subcutaneously (s.c. under the skin) by means of an insulin pump.", 
                "intervention_name": "insulin aspart", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Insulin aspart", 
                "Insulin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "March 10, 2014", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Neuss", 
                    "country": "Germany", 
                    "zip": "41460"
                }
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp When Administered as a Bolus in a Continuous Subcutaneous Infusion Regimen in Subjects With Type 1 Diabetes", 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Global Clinical Registry (GCR, 1452)", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "CSII bolus related baseline corrected area under the serum insulin aspart concentration-time curve", 
            "safety_issue": "No", 
            "time_frame": "From 0 to 30 minutes"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01992588"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "CSII bolus related baseline corrected area under the serum insulin aspart concentration-time curve", 
                "safety_issue": "No", 
                "time_frame": "From 0 to 1 hour"
            }, 
            {
                "measure": "CSII bolus related baseline corrected area under the glucose infusion rate curve", 
                "safety_issue": "No", 
                "time_frame": "From 0 to 1 hour"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}